Table 2.
Univariate Kaplan–Meier (KM) and Cox proportional hazards (PH) models and multivariate Cox PH models for the 21 Chinese HCC patients in this study, HCC patients from Roessler et al. study, and HCC patients from Boyault et al. study
| 21 Chinese patients | Recurrence (n = 21; 9 events) | |
|---|---|---|
| HR (95 % CI) | p value | |
| Univariate Cox PH | ||
| HBV pre-OLT (Yes, No) | 0.285 (0.06, 1.48) | 0.14 |
| Tumor grade (GI, GII GIII) | 1.27 (0.63, 2.01) | 4.50E−02 |
| Age (<49) | 2.33 (0.62, 8.68) | 0.21 |
| Gender (M, F) | 0.29 (0.03, 2.47) | 0.26 |
| HERC5 (Low, High) | 10.34 (1.28, 83.55) | 0.029 |
| Univariate KM | ||
| HERC5 (Low, High) | 0.007 | |
| Multivariate Cox PH | ||
| HERC5 (Low) | 7.29 | 0.07 |
| HBV pre-OLT (Yes, No) | 0.26 | 0.3 |
| Tumor grade | 2.41 | 0.27 |
| Age (<49) | 2.08 | 0.42 |
| Gender (M, F) | 1.86 | 0.7 |
| Roessler et al. study | Survival (n = 224; 86 events) | Recurrence (n = 224; 125 events) | ||
|---|---|---|---|---|
| HR (95 % CI) | p value | HR (95 % CI) | p value | |
| Univariate Cox PH | ||||
| HBV (AVR-CC, CC, No) | 1.32 (0.86, 2.03) | 0.212 | 1.24 (0.86, 1.79) | 0.26 |
| TNM Staging (I, II, III) | 2.34 (1.77, 3.09) | 2.18E−09 | 1.76 (1.41, 2.20) | 7.81E−07 |
| Age (<50) | 1.26 (0.84, 1.88) | 0.262 | 1.01 (0.72, 1.42) | 0.96 |
| Gender (M, F) | 1.86 (0.09, 3.83) | 0.0933 | 2.36 (1.24, 4.50) | 0.009 |
| Cirrhosis (No, Yes) | 0.20 (0.05, 0.80) | 0.0227 | 0.50 (0.23, 1.07) | 0.07 |
| HERC5 (Low, High) | 1.79 (1.17, 2.74) | 0.00706 | 1.55 (1.07, 2.24) | 0.021 |
| Univariate KM | ||||
| HERC5 (Low, High) | 0.0063 | 0.0198 | ||
| Multivariate Cox PH | ||||
| HERC5 (Low) | 2.02 | 0.004 | 1.8 | 0.004 |
| Gender (M, F) | 1.36 | 0.42 | 2.07 | 0.03 |
| Cirrhosis (No, Yes) | 0.28 | 0.076 | 0.56 | 0.17 |
| Age (<50) | 1 | 0.99 | 1.01 | 0.49 |
| HBV (AVR-CC, CC, No) | 1.3 | 0.25 | 1.36 | 0.11 |
| TNM Staging (I, II, III) | 2.32 | 1.06E−08 | 1.74 | 2.21E−06 |
| Boyault et al. study | Survival (n = 41; 20 events) | PFS (n = 41; 20 events) | ||
|---|---|---|---|---|
| HR (95 % CI) | p value | HR (95 % CI) | p value | |
| Univariate Cox PH | ||||
| HBV (Yes, No) | 1.32 (0.51, 3.40) | 0.57 | 1.02 (0.44, 2.38) | 0.96 |
| Gender (M, F) | 1.01 (0.34, 3.03) | 9.88E−01 | 1.30 (0.49, 3.41) | 6.01E−01 |
| Age (<65) | 1.10 (0.45, 2.67) | 0.85 | 1.48 (0.70, 3.17) | 0.31 |
| HERC5 (Low, High) | 2.69 (1.11, 6.51) | 0.029 | 1.96 (0.95, 4.05) | 0.07 |
| Univariate KM | ||||
| HERC5 (Low, High) | 0.023 | 0.07 | ||
| Multivariate Cox PH | ||||
| HERC5 (Low) | 3.31 | 0.018 | 3.8 | 0.01 |
| HBV (Yes, No) | 1.28 | 0.63 | 1.16 | 0.78 |
| Gender (M, F) | 1.22 | 0.74 | 1.32 | 0.64 |
| Age (<65) | 1.02 | 0.42 | 1.02 | 0.4 |
Models indicate predictions of survival, PFS, or HCC recurrence with HERC5 mRNA expression and other relevant clinical factors
Tumor grade is defined by American Joint Committee on Cancer. AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer; 2010; TNM staging levels are defined by the TNM combinations corresponding to one of five stages (stages I–V)
AVR-CC active viral replication chronic carrier, CC chronic carrier, No no HBV